Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 251 to 300 of 635 results for diabetes

  1. Effectiveness of SGLT2 inhibitors for adults with a urine ACR below 3 mg/mmol: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than 3 mg/mmol?

    clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than...

  2. Cirrhosis in over 16s: assessment and management (NG50)

    This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.

  3. Referral criteria for the foot protection service and the multidisciplinary foot care service:- When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    multidisciplinary foot care service:- When and with what criteria should people with diabetes be referred to the foot protection service...

  4. What is the most clinically and cost-effective tool for establishing the severity of peripheral arterial disease and the impact on mortality, morbidity and limb amputation in people with diabetes?

    and the impact on mortality, morbidity and limb amputation in people with diabetes? Any explanatory notes(if applicable) Limited...

  5. How do socioeconomic, environmental, biological and psychosocial factors determine diet and physical activity behaviours and how do they contribute to differences in the risk of developing type 2 diabetes?

    type 2 diabetes? Any explanatory notes(if applicable) None. Source guidance details Comes from guidance Type 2 diabetes...

  6. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

  7. The effects of stopping and/or switching drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision?

    drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug...

  8. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: 29 January 2025

  9. When should testing for gestational diabetes take place – in the first or second trimester?

    Recommendation ID NG3/2 Question When should testing for gestational diabetes take place – in the first or second trimester? Any...

  10. Vitamin D: supplement use in specific population groups (PH56)

    This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.

  11. Medicines and prescribing

    Guidance, advice and support for delivering quality, safety and efficiency in the use of medicines

  12. Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)

    Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.

  13. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

  14. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  15. How effective and cost effective are interventions which use either a 'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower socioeconomic groups?

    'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower...

  16. When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    NG19/2 Question When and with what criteria should people with diabetes be referred to the foot protection service or the...

  17. When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    NG19/2 Question When and with what criteria should people with diabetes be referred to the foot protection service or the...

  18. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  19. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  20. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

  21. Indicator advisory committee members

    Biographies and interests register for the indicator advisory committee

  22. Hypertension in adults. Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines

    are not usually recommended during breastfeeding. For people with type 2 diabetes, ACE inhibitors help protect the kidney. For people of...

  23. Physical activity: for NHS staff, patients and carers (QS84)

    This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.

  24. Improving the physical health of people with serious mental illness: A quality improvement approach

    an inpatient setting through early identification of cardiovascular and diabetes risk factors and subsequent access to information and...

  25. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

  26. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  27. Urinary tract infection (recurrent). Patient decision aid on reducing the chance of recurrent urinary tract infection (UTI) in premenopausal women who are not pregnant

    count towards your daily sugar intake. This could be important if you have diabetes or are overweight. Some of these products have a...

  28. Long-term outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose lowering therapies such as dipeptidyl peptidase‑4 (DPP‑4) inhibitors, sodium–glucose cotransporter‑2 (SGLT2) inhibitors and meglitinides?

    outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose...

  29. Renal replacement therapy and conservative management (NG107)

    This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.

  30. Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]

    Awaiting development [GID-TA10981] Expected publication date: TBC

  31. Thyroid disease: assessment and management (NG145)

    This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.

  32. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  33. Non-invasive tests for diagnosing NAFLD in adults:- Which non-invasive tests are most accurate and cost-effective in identifying non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome?

    non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome? Any explanatory notes(if...

  34. The learning disability health check programme

    NICE recommends that all children, young people and adults with a learning disability should be offered an annual physical health check

  35. How to use quality standards

    How providers and commissioners can use quality standards to improve the quality of care

  36. Bringing our guidance together by topic

    and are piloting the second approach with 2 guideline updates: type 2 diabetes in adults: management (medicines update ) osteoporosis:...

  37. Oral health: local authorities and partners (PH55)

    This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.

  38. The practice establishes and maintains a register of all patients with a diagnosis of non-diabetic hyperglycaemia

    diagnosis of non-diabetic hyperglycaemia Subject(s): Diabetes Date of publication: 31 July 2017

  39. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  40. Implementing transition care locally and nationally using the 'Ready Steady Go' programme

    improved as evidenced in the service evaluation of 'Ready Steady Go' in diabetes (see 6 in supporting materials). The programme enables...

  41. How NICE works

    NICE enables improved access to the best treatments and care. We follow a rigorous decision-making process to develop our guidance. Learn about how we work.

  42. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (IPG569)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

  43. Past appeals and decisions

    November 2005 TA151 (review TA57) Diabetes - insulin pump therapy (review) 16 May 2008 TA063 Diabetes (Type 2) - glitazones...

  44. Embedding NICE guidance into GPSOC clinical systems

    ensure that hypertension, CKD, AKI, asthma, urinary tract infections and diabetes are managed in accordance with NICE guidelines. Our...